Phase III trial comparing the efficacy and safety of recombinant‐ or urine‐derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo‐ovulation and undergoing ovulation induction with follitropin‐alfa

摘要

AimOutside of Japan, recombinant‐human chorionic gonadotropin (r‐hCG) is widely used for the induction of final follicular maturation and early luteinization in women undergoing ovulation induction; whereas in Japan, urine‐derived hCG (u‐hCG) is predominantly used. The primary objective of this study was to demonstrate the non‐inferiority of r‐hCG to u‐hCG for ovulation induction, as assessed by the ovulation rate.